Long-term Safety of Tafamidis in Subjects With Transthyretin Cardiomyopathy

Completed · Phase 3

Conditions studied: Transthyretin (TTR) Amyloid Cardiomyopathy

In brief

Open label study to evaluate tafamidis for the treatment of transthyretin cardiomyopathy

Key facts

Study ID
NCT02791230
Run by
Pfizer
People needed
1733
Starts
2016-06-13
Expected to finish
2023-11-02
Last updated by the study team
2025-02-03

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.